Caribou Biosciences' Drug CB-010 Receives FDA's IND Clearance for Lupus Nephritis Treatment
Thursday, 4 April 2024, 20:07
Caribou Biosciences' Lupus Treatment Progress
Caribou Biosciences has recently received IND clearance from the FDA for its drug CB-010, designed to target lupus nephritis. This paves the way for a Phase 1 clinical trial scheduled for 2024, bringing new possibilities for lupus treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.